Last updated on April 2016

A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women


Brief description of study

Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal women. Clinical evidence indicates potent antagonists of 5-HT2A are more likely to cause hypothermia. Risperidone is a potent 5-HT2A and a dopamine D2 receptor antagonist and is proposed to have effect on reduciton of hot flashes through its dopaminergic and serotonergic antagonism. The primary purpose of this study is to determine if RCN3028 is effective and safe in the treatment of moderate to severe vasomotor symptoms associated. In accordance with the latest FDA guidance study participants will have a minimum of 7 moderate to sever hot flashes per day, or 50 per week at baseline.

Clinical Study Identifier: NCT02100540

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Hung-Ming Wu, MD, PhD

Changhua Christian Hospital
Changhua, Taiwan
  Connect »